HaiHe Biopharma 
Welcome,         Profile    Billing    Logout  
 1 Product   17 Diseases   1 Product   2 Trials   44 News 


«1234567»
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Journal:  NFκB-Activated COX2/PGE/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues. (Pubmed Central) -  Apr 7, 2021   
    PGE blockade allowed for the selectively enhanced migration of CTLs to the BCG-treated BlCa samples and eliminated the enhanced migration of Tregs. Since the balance between the CTLs and suppressive cells in the TME predicts the outcomes in patients with BlCa and other diseases, our data help to elucidate the mechanisms which limit the effectiveness of BCG therapies and identify new targets to enhance their therapeutic effects.
  • ||||||||||  HH185 / CSPC Pharma, HaiHe Biopharma
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 23, 2021   
    P1,  N=42, Recruiting, 
    These identified drugs could be repurposed to treat COVID-19 patients. Trial completion date: Sep 2020 --> Dec 2022 | Trial primary completion date: Apr 2020 --> Jun 2022
  • ||||||||||  HH2853 / HaiHe Biopharma, Shanghai Inst. of Materia Medica
    Trial completion date, Trial primary completion date, Metastases:  Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov) -  Mar 9, 2021   
    P1,  N=30, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  delpazolid (LCB01-0371) / LegoChem Biosci
    Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy:  PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) (clinicaltrials.gov) -  Feb 25, 2021   
    P2b,  N=75, Not yet recruiting, 
    Trial completion date: Dec 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2022 Trial completion date: Sep 2022 --> Jan 2023 | Initiation date: Feb 2021 --> Jun 2021 | Trial primary completion date: Jan 2022 --> May 2022
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  KEYNOTE-888: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (clinicaltrials.gov) -  Feb 21, 2021   
    P1b/2,  N=18, Terminated, 
    Trial completion date: Nov 2021 --> Feb 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2021 --> Feb 2021; Based on the totality of the generated combined safety and efficacy data in the interim period, the company decided to terminate the combination study in NSCLC patients. There are no subjects on study drug at this time or in the EOT Follow-up period.
  • ||||||||||  HH2710 / HaiHe Biopharma
    Trial completion date, Trial primary completion date, Metastases:  A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (clinicaltrials.gov) -  Feb 8, 2021   
    P1/2,  N=150, Recruiting, 
    Studies with SCC44 in patients with METex14 skipping mutation in NSCLC are ongoing to further explore the safety and efficacy in larger populations. Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Jun 2021
  • ||||||||||  HH2853 / HaiHe Biopharma, Shanghai Inst. of Materia Medica
    Trial completion date, Trial primary completion date, Metastases:  Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov) -  Feb 8, 2021   
    P1,  N=30, Recruiting, 
    Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Jun 2021 Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
  • ||||||||||  lucitanib (E 3810) / Clovis, HaiHe Biopharma, Servier
    Journal:  A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated. (Pubmed Central) -  Feb 4, 2021   
    We newly proposed a pentapeptide mn with superb αvβ3-binding affinity and tailored AL3810-loaded mn-modified liposome that afforded impervious blood circulation, targeting ability, and glioma therapeutic expertise as vastly alleviated immune opsonization on the underpinning of the finite antibodies and complements assembly. Stemming from attenuated immunogenicity, peptide mn strengthened liposome functions as a promising nanocarrier platform for molecular targeting agents.
  • ||||||||||  delpazolid (LCB01-0371) / LegoChem Biosci
    Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy:  PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) (clinicaltrials.gov) -  Nov 29, 2020   
    P2b,  N=75, Not yet recruiting, 
    However, the FDA approval of erdafitinib for the treatment of urinary bladder cancers may stimulate additional work targeting the many other FGFR-driven neoplasms. Trial completion date: May 2022 --> Sep 2022 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: Sep 2021 --> Jan 2022
  • ||||||||||  Review, Journal:  Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence. (Pubmed Central) -  Nov 28, 2020   
    Delafloxacin, omadacycline and lefamulin are the most recently approved antibiotics for CAP...New antimicrobials, such as solithromycin and nemonoxacin, are currently being studied in Phase III clinical trials...These include zabofloxacin, aravofloxacin, nafithromycin, TP-271, gepotidacin, radezolid, delpazolid, and CAL02. The preliminary results of these clinical trials allow us to assure that most of these drugs may play a role in the future treatment of CAP.
  • ||||||||||  HH2853 / HaiHe Biopharma, Shanghai Inst. of Materia Medica
    Enrollment open, Metastases:  Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov) -  Aug 27, 2020   
    P1,  N=30, Recruiting, 
    Clinical trial identification: NCT03260179. Not yet recruiting --> Recruiting
  • ||||||||||  delpazolid (LCB01-0371) / LegoChem Biosci
    Enrollment closed, Trial completion date, Trial primary completion date:  A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace (clinicaltrials.gov) -  Aug 8, 2020   
    P1,  N=6, Active, not recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Oct 2020 | Trial primary completion date: Oct 2021 --> Oct 2020
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases:  KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov) -  Aug 8, 2020   
    P1b,  N=53, Recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Oct 2020 | Trial primary completion date: Oct 2021 --> Oct 2020 Trial completion date: Aug 2020 --> Nov 2021 | Trial primary completion date: Aug 2020 --> Jul 2021
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases:  KEYNOTE-888: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (clinicaltrials.gov) -  Aug 8, 2020   
    P1b/2,  N=41, Recruiting, 
    Trial completion date: Aug 2020 --> Nov 2021 | Trial primary completion date: Aug 2020 --> Jul 2021 N=25 --> 41 | Trial completion date: Sep 2020 --> Nov 2021 | Trial primary completion date: Sep 2020 --> Jul 2021